How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.70. The biopharmaceutical company earned $11.26 million during the quarter, compared to analyst estimates of $5.46 million. BioSpecifics Technologies had a trailing twelve-month return on equity of 14.81% and a net margin of 47.43%.

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV) , NVIDIA (NVDA) , Pfizer (PFE) , Biogen (BIIB) , Johnson & Johnson (JNJ) , Horizon Therapeutics Public (HZNP) , Inovio Pharmaceuticals (INO) , Intel (INTC) , Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP) .

NASDAQ:BSTC

BioSpecifics Technologies (BSTC) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free BSTC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $88.53
▼
$88.53
50-Day Range: $88.22
▼
$88.53
52-Week Range: $42.00
▼
$89.15

Volume: N/A
Average Volume: 61,105 shs
Market Capitalization: $650.25 million

P/E Ratio: 37.51
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get BioSpecifics Technologies alerts:

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About BioSpecifics Technologies Stock (NASDAQ:BSTC)

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

BSTC Stock News Headlines

March 21, 2023 | bizjournals.com

Silicon Valley Technology News

See More Headlines

Receive BSTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSpecifics Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2020
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:BSTC
CUSIP: 09093110
CIK: 875622
Web: www.biospecifics.com
Phone: 302-842-8450
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $3.33
Trailing P/E Ratio: 37.51
Forward P/E Ratio: 61.91
P/E Growth: N/A
Net Income: $24.47 million
Net Margins: 47.43%
Pretax Margin: N/A
Return on Equity: 14.81%
Return on Assets: 14.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 66.24
Quick Ratio: 66.24

Sales & Book Value

Annual Sales: $38.19 million
Price / Sales: 17.03
Cash Flow: $3.38 per share
Price / Cash Flow: 26.18
Book Value: $18.42 per share
Price / Book: 4.81

Miscellaneous

Outstanding Shares: 7,345,000
Free Float: N/A
Market Cap: $650.25 million
Optionable: Not Optionable
Beta: 0.24

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Ronald Law J.D. (Age 67)
Ph.D., Sr. VP of Bus. Devel.
Comp: $487.38k
Mr. Joseph Truitt (Age 55)
CEO & Director
Mr. Patrick C. Hutchison (Age 61)
Chief Financial Officer
Mr. Alex Monteith
Sr. VP & Chief Bus. Officer
Carl A. Valenstein
Corp. Sec.

Key Competitors

View All Competitors

BSTC Stock Analysis - Frequently Asked Questions

How were BioSpecifics Technologies' earnings last quarter?: BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.70. The biopharmaceutical company earned $11.26 million during the quarter, compared to analyst estimates of $5.46 million. BioSpecifics Technologies had a trailing twelve-month return on equity of 14.81% and a net margin of 47.43%.
What other stocks do shareholders of BioSpecifics Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), NVIDIA (NVDA), Pfizer (PFE), Biogen (BIIB), Johnson & Johnson (JNJ), Horizon Therapeutics Public (HZNP), Inovio Pharmaceuticals (INO), Intel (INTC), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

This page (NASDAQ:BSTC) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioSpecifics Technologies (BSTC) Stock Price, News & Analysis

About BioSpecifics Technologies Stock (NASDAQ:BSTC)

BSTC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BSTC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info